אוקספה
Country: Iżrael
Lingwa: Ebrajk
Sors: Ministry of Health
Xi dokumenti għal dan il-prodott mhumiex disponibbli bħalissa, tista 'tibgħat talba lis-servizz tal-konsumatur tagħna u aħna ninnotifikawkom malli nkunu nistgħu niksbuhom.
Ibgħat talba.
Ibgħat talba.
Ingredjent attiv:
ACID CASEIN 5.9 G / 100 ML; ARTIFICIAL VANILLA 116 MG / 100 ML
Disponibbli minn:
ABBOTT MEDICAL LABORATORIES LTD
Kodiċi ATC:
B05XA30
Għamla farmaċewtika:
LIQUID
Rotta amministrattiva:
TUBE FEEDING
Manifatturat minn:
ABBOTT NUTRITION - ABBOTT LABORATORIES, USA
Grupp terapewtiku:
COMBINATIONS OF ELECTROLYTES
Indikazzjonijiet terapewtiċi:
Oxepa is clinically shown to modulate the inflammatory response in critically ill, mechanically ventilated patients. It is appropriate for patients who have sepsis, ALI (acute lung injury), or ARDS (acute respiratory distress syndrome).
Data ta 'l-awtorizzazzjoni:
2012-01-01
